acorda.comAcorda Therapeutics Biotechnology Company | MS and Spinal Cord Injury Treatments

 Toggle navigation menu Go Home About Acorda About Acorda Company Leadership Company Leadership Management Team Board of Directors Partnering With Acorda Grant Program Scientific Award Compliance Compliance Acorda Compliance Biotie EFPIA Disclosures Message from BIO Diversity and Inclusion Contact Us For Patients For Patients Focus On Therapies In the Community Resources Policy on Access to Unapproved or Uncommericalized Medicines Products & Research Products & Research Pipeline ARCUS ® Technology Products Products AMPYRA® (dalfampridine) INBRIJA™ (levodopa inhalation powder) Terms and Conditions (Product Purchases) Clinical Trials Investors Investors Corporate Governance Stock Information Investor Events Investor News Financial Information Financial Information Quarterly Reports Annual Reports SEC Filings Analysts Investor Resources Investor Resources Investor Kit E-mail Alerts FAQs IR Contact News & Events News & Events In the News Awards Press Releases Social Media Careers Careers Working at Acorda Our Employees Benefits Job Openings Application Privacy Policy Terms of Use Site Map Contact Us About Acorda The one thing you should know about Acorda Therapeutics is that everything we do is aimed at improving the lives of millions of people with nervous system disorders... LEARN MORE › Careers We look for talented, Motivated people who want to make a difference in people's lives... LEARN MORE › Find out about INBRIJA™ LEARN MORE › Products & Research We have a deep understanding and experience in nervous systems research, product development and commercialization... LEARN MORE › Investors Acorda Therapeutics, Inc. is a biotechnology company whose mission is to develop and market therapies... LEARN MORE › For Patients We founded Acorda to bring life-changing therapies to people living with a wide range of nervous system disorders... LEARN MORE › News & Events Acorda maintains open dialogue with patients, caregivers, healthcare professionals and investors... LEARN MORE › Tuesday, August 4, 2020 Acorda Reports Second Quarter 2020 Financial Results MORE NEWS -- Wednesday, March 25, 2020 COVID-19 Update for Patients Taking AMPYRA or INBRIJA MORE NEWS My parents always told me… that you should do in life what you love. There’s no point in doing something in your life that you don’t. And that’s what I get to do here… See the Video See the Video My parents always told me... that you should do in life what you love. There's no point in doing something in your life that you don't. And that's what I get to do here... See the Video -- About Acorda Company Leadership Management Team Board of Directors Partnering With Acorda Grant Program Scientific Award Compliance Acorda Compliance Biotie EFPIA Disclosures Message from BIO Diversity and Inclusion Contact Us For Patients Focus On Therapies In the Community Resources Policy on Access to Unapproved or Uncommericalized Medicines Products & Research Pipeline ARCUS® Technology Products AMPYRA® (dalfampridine) INBRIJA™ (levodopa inhalation powder) Terms and Conditions (Product Purchases) Clinical Trials Investors Corporate Governance Stock Information Investor Events Investor News Financial Information Quarterly Reports Annual Reports SEC Filings Analysts Investor Resources Investor Kit E-mail Alerts FAQs IR Contact News & Events In the News Awards Press Releases Social Media Careers Working at Acorda Our Employees Benefits Job Openings Application Privacy Policy Terms of Use Site Map Contact Us Alert Alert × CLOSE -- CLOSE ... You are now leaving the Acorda.com site. By clicking "Ok", you will be leaving this website (sponsored by Acorda Therapeutics, Inc.) to enter an external and entirely independent website. Acorda.com provides this link as a service and assumes no responsibility for any information presented on external websites. OK Cancel If you’ve been impacted by Hurricane Harvey, Irma, or Maria, and have concerns about your Ampyra (dalfampridine) prescription, please contact your Specialty Pharmacy or Ampyra Patient Support Services at (888) 881-1918 Continue to www.acorda.com Acorda has acquired Biotie Therapies. We invite you to explore www.acorda.com to learn more about our company, including our continued development of BIotie clinical programs for tozadenant, SYN120 and BTT1023. Information regarding transfers of value made to healthcare professionals and healthcare organizations in connection with Biotie’s clinical development programs is also available. The website uses cookies, which are text files placed on your computer. Some of these are essential to the site’s operation while others analyse how visitors use the site. These cookies are set by default but you can disable them or view more information about how they are used here . By clicking on continue you consent to our use of cookies. Click here to access Biotie’s EFPIA Disclosure Page Continue to www.acorda.com CLOSE ... Acorda Named One of 100 Best Workplaces for Women 2015 Click for more information...